Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash & Equivalents: 2012-2025

Historic Cash & Equivalents for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $48.5 million.

  • CorMedix's Cash & Equivalents rose 37.43% to $48.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year increase of 37.43%. This contributed to the annual value of $40.7 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, CorMedix's Cash & Equivalents is $48.5 million, which was down 69.56% from $159.3 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Cash & Equivalents registered a high of $159.3 million during Q2 2025, and its lowest value of $19.7 million during Q2 2023.
  • Over the past 3 years, CorMedix's median Cash & Equivalents value was $38.0 million (recorded in 2024), while the average stood at $51.2 million.
  • In the last 5 years, CorMedix's Cash & Equivalents soared by 524.48% in 2021 and then crashed by 59.74% in 2023.
  • CorMedix's Cash & Equivalents (Quarterly) stood at $53.3 million in 2021, then dropped by 19.07% to $43.1 million in 2022, then climbed by 23.26% to $53.3 million in 2023, then slumped by 33.81% to $40.7 million in 2024, then surged by 37.43% to $48.5 million in 2025.
  • Its Cash & Equivalents stands at $48.5 million for Q3 2025, versus $159.3 million for Q2 2025 and $66.3 million for Q1 2025.